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Abstract: Malaria is a mosquito-borne infectious disease caused by the parasite Plasmodium spp.
Malaria continues to have a devastating impact on human health. Sporozoites are the infective forms
of the parasite inside mosquito salivary glands. Circumsporozoite protein (CSP) is a major and
immunodominant protective antigen on the surface of Plasmodium sporozoites. Here, we report a
generation of specific monoclonal antibodies that recognize the central repeat and C-terminal regions
of P. falciparum CSP. The monoclonal antibodies 3C1, 3C2, and 3D3—specific for the central repeat
region—have higher titers and protective efficacies against challenge with sporozoites compared
with 2A10, a gold standard monoclonal antibody that was generated in early 1980s.
Keywords: Plasmodium falciparum; circumsporozoite protein; CSP; monoclonal antibody; 2A10; 3C1;
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1. Introduction
In 2015, there were 214 million new cases of malaria (range 149–303 million) and an estimated
438,000 malaria deaths (range 236,000–635,000) worldwide [1]. Malaria is a mosquito-borne disease
caused by the protozoan parasite, Plasmodium spp. Malaria is transmitted among humans by the bite
of female mosquitoes of the genus Anopheles. The battle against malaria has been fought using a wide
range of interventions, including insecticide-treated bed nets, indoor residual spraying, effective
medicines, and vaccine [2–5]. However, emerging antimalarial drug resistance and insecticide
resistance threaten malaria control and public health [6–8]. The only approved malaria vaccine
is RTS,S/A01 (trade name Mosquirix) to date. RTS,S/A01 represents it’s composed of P. falciparum
CSP repeat region (R), T-cell epitopes (T) fused to the hepatitis B surface antigen (S) and assembled
with un-fused copies of hepatitis B surface antigen, and a chemical adjuvant (AS01) is added to
increase the immune system response. The efficacy of RTS,S/AS01 against all episodes of severe
malaria is approximately 50% in young children in Africa [9–11]. A completely effective vaccine is not
yet available for malaria. The novel vectored immunoprophylaxis, an adeno-associated virus-based
technology to introduce effective antibody genes in mammalian host, has been added to currently
available tools to control malaria [12]. A highly efficient neutralization antibody is one of the essential
components of the vectored immunoprophylaxis [12]. Sporozoites are the infectious form of the
parasites inside mosquito salivary glands. The circumsporozoite protein (CSP) is a major protein
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on the surface of Plasmodium sporozoites and an immunodominant protective antigen in irradiated
sporozoites [13]. The overall structure of CSP is conserved among Plasmodium species, consisting of a
species-specific central tandem repeat region flanked by conserved N-terminus and C-terminus [14].
The N-terminus is proteolytically processed during sporozoite invasion into host cells, unmasking the
C-terminal cell-adhesive domain [15,16]. The C-terminus contains a thrombospondin repeat domain
and T cell epitopes. The central repeat region, which is composed of approximately 30 tandem repeats
of asn-ala-asn-pro (NANP), corresponds to highly immune-dominant B-cell epitopes [17,18].
The transmission of malaria from mosquito to mammalian host can be prevented by antibodies
against CSP, such as the monoclonal antibody (mAb) 2A10 [12,19]. The mouse mAb 2A10 is directed
against the central repeat region of P. falciparum CSP (PfCSP) [12,20–22]. The mouse mAb 2A10 is a
useful tool for the study of PfCSP in a mouse model. Delivery of adeno-associated virus expressing
2A10 into mice results in long-lived mAb expression and protection from sporozoite challenge.
Vectored immunoprophylaxis provides an exciting new approach to the urgent goal of effective
malaria control [12]. However, the mice expressing the CSP-specific mAb 2A10 lower than 1 mg/mL
could not be completely protected [12]. Thus, highly potent CSP-specific antibodies are desired for
the immunoprophylaxis to control this infectious disease. Here, we report a generation of novel and
potent CSP-specific antibodies against PfCSP. In addition, we characterized the mAbs’ subclasses,
titers, and protections for sporozoite challenge. Importantly, the protective efficacies of 3C1, 3C2, and
3D3 were found to be better than the reference mAb 2A10.
2. Materials and Methods
2.1. Expression and Purification of Recombinant PfCSP
PfCSP coding sequence without glycosylphosphatidylinositol (GPI) anchor (GenBank: M19752.1)
was amplified using Phusion® high fidelity DNA polymerase (Cat#M0530S, New England Biolabs,
Ipswich, MA, USA) with specific primers containing EcoR I and Not I restriction enzyme recognition
sites. The PCR product was purified using Qiagen PCR cleanup kit (Qiagen, Germantown, MD, USA).
Both the PCR product and pET20b vector were digested with restriction endonucleases EcoR I and
Not I (New England Biolabs) according to the manufacturer’s protocol. After gel purification, the
digested PCR product was ligated into the linearized pET20b vector using Roche rapid DNA ligation
kit (Cat. No. 11635379001, Roche, Branford, CT, USA), and then transformed into Top10F’ chemically
competent E. coli. (Invitrogen, Grand Island, NY, USA) and plated onto Luria-Bertani (LB) agar plates
containing ampicillin. A single colony was picked from the plate and inoculated into LB broth plus
ampicillin. The recombinant plasmid was purified from the overnight culture using Qiagen plasmid
purification kit. The purified plasmid was validated by DNA sequencing and transformed into the
BL21(DE3) strain for protein expression. When the culture reached an optical density (OD, 600 nm) of
0.5–0.6, PfCSP expression was induced using IPTG (1 mM) at 20 ◦C. Then the overnight culture was
pelleted by centrifugation and lysed with lysozyme buffer and followed by sonication. Lysate was
cleared by centrifugation and the His-tagged PfCSP was purified using Ni2+-affinity chromatography
(Qiagen, Germantown, MD, USA).
PfCSP purification: 25 mL of nickel nitrilotriacetic acid (Ni-NTA) agarose beads were loaded onto
a 22 mL phenyl sepharose column (Pharmacia/Pfizer, New York, NY, USA), washed and equilibrated
by 200 mL of His Elution Buffer (50 mM TRIS hydrochloride (Tris-HCl) (pH 8.0), 300 mM imidazole,
50 mM NaCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), and 1 mM phenylmethane sulfonyl
fluoride (PMSF) and 500 mL of His Binding Buffer (50 mM Tris-HCl (pH 8.0), 5 mM imidazole. 100 mM
NaCl, 0.1 mM EDTA, and 1 mM PMSF). Then the clarified lysate from 1 L culture was added to the
column and washed with 250 mL of His Binding Buffer followed by 500 mL of His Wash Buffer (50 mM
Tris-HCl (pH 8.0), 20 mM imidazole. 300 mM NaCl, 0.1 mM EDTA, and 1 mM PMSF). Then, the
bound protein was eluted with 20 × 15 mL of His Elution Buffer (50 mM Tris-HCl (pH 8.0), 200 mM
imidazole. 300 mM NaCl, 0.1 mM EDTA, and 1 mM PMSF). Proteins were resolved on sodium dodecyl
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sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie Brilliant Blue staining.
Tris-HCl, EDTA, and PMSF are from Sigma-Aldrich, St. Louis, MO, USA.
2.2. Generation of Hybridomas
The recombinant PfCSP was shipped to Green Mountain Antibodies, Inc. (Burlington, VT, USA)
for the immunization of mice, followed by the fusion to generate monoclonal antibodies. Briefly, mice
were primed with 50 µg of PfCSP emulsified with complete Freund’s adjuvant, followed by weekly
immunization of 50 µg of PfCSP emulsified with TiterMax® (Sigma-Aldrich, St. Louis, MO, USA) and
SAS® (Sigma-Aldrich) (alternate week). One week after administering seven doses of immunization,
the lymph node was isolated. B cells were purified from using anti-B220 magnetic-activated cell sorting
(MACS), and then fused with a mouse myeloma cell line. Cloning was achieved by limiting dilution.
After re-cloning, positive clones that secrete immunoglobulin G (IgG) against the full-length PfCSP
were selected by enzyme-linked immunosorbent assay (ELISA) (Table 1).
2.3. ELISA Assay
The ELISA plates were first coated with peptides representing PfCSP N-terminal, the central
repeat, or C-terminal regions (10 µg/mL) and then blocked with 3% bovine serum albumin
(BSA) in phosphate buffered saline with Tween-20 (PBST) (Table 2). MAbs were 10-fold diluted
(0.1–1000 ng/mL) and added to the plates and incubated for 1 h. After washing the plates,
horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc Fragment was added. One hour
later, tetramethylbenzidine (TMB) High Sensitivity Substrate was added, and ODs were read at 450 nm.
Peptide AIAWAKARARQGLEW was used as a negative control. The mAb 2A10 was used as a positive
control [19,23].
2.4. Immuno-Fluorescence Assay
1 × 104 salivary gland PfCSP/Py sporozoites were loaded on MP biomedical multi-test glass
slides (MP Biomedicals, Santa Ana, CA, USA). PfCSP/Py is an infectious P. yoelii parasite bearing a
full length of P. falciparum circumsporozoite protein (25). After air drying at room temperature, the
slides were fixed with 4% paraformaldehyde for 10 min at room temperature, and then blocked with
3% BSA in PBST. The mAbs were two-fold diluted from 1.31 mg/mL to 5 ng/mL, and added to the
PfCSP/Py sporozoites-coated wells on the slides for 45 min. After washing with PBS containing 0.05%
Tween-20 three times, the slides were incubated with Alexa Fluor 594 conjugate goat anti-mouse IgG
(H + L) antibody. One hour later, the slides were washed and mounted in PBS containing 50% glycerol
and 1% (w/v) p-phenylenediamine to reduce bleaching.
2.5. Sporozoite Neutralization Assays
In vitro neutralization assays were conducted by pre-incubating 2 × 104 PfCSP/Py sporozoites
with 100 µg mAb on ice for 45 min, and then adding to 1 × 105 Hepa1-6 cells. Forty-two hours post
infection, liver stage parasite burden wear measured by quantitative polymerase chain reaction
(qPCR) of P. yoelii 18S rRNA as previously described [24]. Mouse glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal control. In vivo neutralization assays were
conducted by pre-incubating 50 PfCSP/Py sporozoites dissected from infected mosquito salivary
glands with 5 or 50 µg mAb on ice for 45 min, and then intravenously injecting into BALB/c mouse.
The presence of parasite in blood was determined by Giemsa staining of the blood smear of the
recipient mouse.
2.6. Giemsa Stain
Starting three days after sporozoite challenge, a drop of blood was collected from the mouse tail
vein for thin blood smears on pre-cleaned glass slides. Thin blood smears were fixed with absolute
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methanol and then stained with diluted Giemsa stain (1:20, v/v) for 20 min. % parasitemia (% of
parasitized red blood cells among total red blood cells) were examined with a 100× oil immersion
objective under the microscope.
3. Results
3.1. Generation of Hybridomas
PfCSP was expressed and purified from E. coli. (Figure 1), and then immunized BALB/c mice.
The immune spleen cells from the mice producing anti-PfCSP antibodies were fused with myeloma
cells, and six hybridoma cell lines (2D4, 3C1, 3C2, 3D3, 4C1, 4C6) were cloned. The mAbs 4C6 2D4
3D3 were identified as belonging to subclass IgG1. The mAbs 3C2 and 4C1 were isotyped as IgG2b
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Figure  1.  Expression  and  purification  of  a  recombinant  P.  falciparum  circumsporozoite  protein 
(PfCSP). (A) Schematic representation of the recombinant PfCSP. Pf CSP coding sequence excluding 
C‐terminal glycosylphosphatidylinositol (GPI) anchor, composed of N‐terminal, central repeat, and 
C‐terminal  regions, was  fused with  6XHis  tag  at  its C‐terminus,  and  cloned  into  pET20b  vector 
(Stratagene, La Jolla, CA, USA); (B) Schematic representation of the PfCSP expression plasmid in this 
study. The full length of PfCSP without GPI anchor was cloned into pET20b vector between EcoR I 
and Not  I;  (C) Expression and purification of a  recombinant PfCSP  from E.  coli. The  recombinant 




Name of the mAb Titer (IFA) Titer (ELISA) Subclass
2A10  40 ng/mL  10 ng/mL  IgG2a 
4C6  80 ng/mL  1 μg/mL  IgG1 
2D4  80 ng/mL  500 ng/mL  IgG1 
3C2  10 ng/mL  1 ng/mL  IgG2b 
4C1  328 μg/mL  200 ng/mL  IgG2b 
3C1  5 ng/mL    5 ng/mL  IgG3 
3D3  10 ng/mL  2 ng/mL  IgG1 
Figure 1. Exp ssion and purification of a recombinant P. falciparum cir umspor ite protein (PfCSP).
(A) Schematic representation of the rec mbinant PfCSP. Pf coding sequence excluding C-terminal
glycosylphosphatidylinositol (GPI) anchor, composed of N-terminal, central repeat, and C-terminal
regions, was fused with 6XHis tag at its C-terminus, and cloned into pET20b vector (Stratagene, La Jolla,
CA, USA); (B) Sc ematic representation of the PfCSP expressio plasmid in this study. The full length
of PfCSP without GPI anchor w s cloned into pET20b vector between EcoR I and Not I; (C) Expression
and purification of a recombinant PfCSP from E. coli. The recombinant PfCSP was expressed in BL21
(DE3), and then purified by Ni-Affinity Chromatography. Lane 1, Protein marker; Lane 2, crude
extract; Lane 3, flow through; Lane 4–7, washes; Lane 8, elute. Data are representative from three
independent experiments.
Table 1. The titers of the PfCSP-specific mAbs *.
Name of the mAb Titer (IFA) Titer (ELISA) Subclass
2A10 40 ng/mL 10 ng/mL IgG2a
4C6 80 ng/mL 1 µg/mL IgG1
2D4 80 ng/mL 500 ng/mL IgG1
3C2 10 ng/mL 1 ng/mL IgG2b
4C1 328 µg/mL 200 ng/mL IgG2b
3C1 5 ng/mL 5 ng/mL IgG3
3D3 10 ng/mL 2 ng/mL IgG1
* PfCSP: P. falciparum circumsporozoite protein; IgG: immunoglobulin G; IFA: immunofluorescence assay; mAb:
monoclonal antibody.
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3.2. Specificity of Anti-PfCSP mAbs
The specificity of the mAbs has been explored by measuring their reaction with peptides covering
PfCSP N-terminal, the central repeat, and C-terminal regions (Table 2). The mAbs 2D4, 4C1, and 4C6
recognized the PfCSP C-terminal region. The mAbs 3C1, 3C2, and 3D3 recognized the PfCSP central
repeat region (Figure 2).
Table 2. Synthetic peptides representing PfCSP.





































3C2;  (F), 3D3;  (G), 2A10. The mAb 2A10 was used as a positive control. ELISA was performed  in 
duplicate. Data are representative of three independent experiments. OD, Optical density. 
3.3. Titration of the PfCSP‐Specific mAbs 
The  antibody  titer  was  tested  by  enzyme‐linked  immunosorbent  assay  (ELISA)  and 
immunofluorescence  assay  (IFA)  (Table  1  and  Figure  3). ELASA using peptides  covering PfCSP 
showed that the titers of mAbs recognizing the PfCSP central repeat region were higher than those 
recognizing the PfCSP C‐terminal region. The titers of the three mAbs recognizing the PfCSP central 
repeat were higher  than  the  control  2A10  (3C2  >  3D3  >  3C1  >  2A10).  IFA using  the Plasmodium 
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Figure 2. Specificity of anti-PfCSP monoclonal antibodies (mAbs) by enzyme-linked immunosorbent
assay (ELISA). Peptides representing PfCSP N-terminal, central repeat, and C-terminal regions were
used to evaluate specificity of anti-PfCSP mAbs (Table 1). (A), 2D4; (B), 4C1; (C),4C6; (D), 3C1; (E), 3C2;
(F), 3D3; (G), 2A10. The mAb 2A10 was used as a positive control. ELISA was performed in duplicate.
Data are representative of three independent experiments. OD, Optical density.
3.3. Titration of the PfCSP-Specific mAbs
The antibody titer was tested by enzyme-linked immunosorbent assay (ELISA) and
immunofluorescence assay (IFA) (Table 1 and Figure 3). ELASA using peptides covering PfCSP showed
that the titers of mAbs recognizing the PfCSP central repeat region were higher than those recognizing
the PfCSP C-terminal region. The titers of the three mAbs recognizing the PfCSP central repeat were
higher than the control 2A10 (3C2 > 3D3 > 3C1 > 2A10). IFA using the Plasmodium sporozoites expressing
PfCSP [25] also showed that the titers of the mAbs recognizing the PfCSP central repeat were higher
than those recognizing the PfCSP C-terminal region. The titer of the three mAbs recognizing the PfCSP
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Figure 3. Immunofluorescence assays. PfCSP/Py (a P. yoelii parasite bearing P. falciparum
circumsporozoite protein) salivary gland sporozoites [25] were incubated with 160 ng/mL mAbs, except
4C1 at 328 µg/mL, followed by incubation with Alexa Fluor 594 goat anti-mouse IgG (H + L) antibody.
3.4. Protection of the PfCSP mAbs against PfCSP/Py Sprozoite Challenge
We then examined the protection of the PfCSP mAbs against malaria sporozoite challenge in vitro
and in vivo. For the malaria sporozoite challenges, we used the highly infectious hybrid PfCSP/Py
sporozoite, which is based on rodent P. yoelii parasite and its CSP is replaced by the full-length of CSP
from P. falciparum [25]. We found that mAb 3C1, 3C2, and 3D3 significantly inhibited the parasite
development in Hepa 1–6 cells compared with 2A10, which is an effective mouse mAb specific for the
PfCSP central repeat [19,23] (Figure 4). This was in agreement with the in vivo neutralization assay
(Table 3 and Figure 5). Fifty µg of 3C1, 3C2, and 3D3 completely protected the mice from PfCSP/Py
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sporozoite challenge. The protective effect of 3C1, 3C2, and 3D3 were better than the previously
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Days Post Challenge  Day 3  Day 4 Day 5 Day 14 Day 3 Day 4 Day 5  Day 14
2A10  0 *,#  4  5  5  0  0  3  3 
4C6  0  5  5  5  0  1  4  4 
2D4  0  4  5  5  0  0  3  3 
3C2  0  1  5  5  0  0  0  0 
4C1  0  5  5  5  0  3  4  4 
3C1  0  1  4  4  0  0  0  0 
3D3  0  2  5  5  0  0  0  0 
Naiive  0  5  5  5  0  5  5  5 
* Five mice per group. # The number of infected mice. 
Figure 4. In vitro neutralization assay. 2 × 104 PfCSP/Py sporozoites were pre-incubated with 100 µg
of each mAb, and then added to Hepa1-6 cells. Forty-two hours post infection, liver stage parasite
burden wear measured by P. yoelii 18S rRNA/mouse glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Naive mouse serum was used as control. The in vitro neutralization assay was performed
in triplicate. Data are representative of two independent experiments.
Table 3. In vivo neutralization assay.
ount of mAb 5 µg 0 µg
s Post Challenge Day 3 Day 4 Day 5 Day 14 Day 3 y 4 D Da
2A10 0 *,# 4 5 5 0 0 3 3
4C6 0 5 5 5 0 1
2D4 0 4 5 5 0 0 3 3
3C2 0 1 5 5 0 0 0 0
4C1 0 5 5 5 0 3 4 4
3C1 0 1 4 4 0 0 0 0
3D3 0 2 5 5 0 0 0 0
Naiive 0 5 5 5 0 5 5 5
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mAbs against PfCSP, which we generated  in  this study, are  found  to be more potent  than 2A10. 
Figure 5. Parasitemia of mice in the neutralization assay. Fifty PfCSP/Py sporozoites were incubated
with 50 µg mAbs followed by i.v. injection into BALB/c mice (five mice per group). Parasitemia were
counted by Giemsa stains of mouse tail blood followed by microscopy. Data are parasitemia of the
mice four and five days post challenge. Naive mice were i.v. injected with 50 PfCSP/Py sporozoites as
positive controls.
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4. Discussion
The CSP consists of the N-terminal flanking region, the central region that contains repetitive
immunodominant B-cell epitopes, and the C-terminal flanking region that contains multiple T-cell
epitopes. The N-terminus of the CSP is proteolytically processed during the sporozoite invasion
into host cells [15,16]. This may explain why we did not obtain specific antibodies against the
N-terminus. The abundant NANP repeats present within the central region are likely to contribute
to the high neutralization efficacies of the mAbs against PfCSP central repeat region, as previously
published [26,27]. In fact, mAbs, which recognize the PfCSP central repeat region, have been shown
to exert a potent neutralization activity against the sporozoites [26,27]. All the mAbs 3C1, 3C2, 3D3,
and 2A10, recognize the central repeat region of the PfCSP. Fifty µg of the novel mAbs 3C1, 3C2,
and 3D3 completely protected the mice from PfCSP/Py sporozoites challenge; while the reference
mAb 2A10 only partially protected the mice. A likely explanation is that the native structure of the
central repeats of the CSP is not in a random coil state, and the repeat region is predicted to form
a rod-like structure [28]. It is speculated that these mAbs recognize structurally different epitopes
coded by NANP repeat, resulting in different protection efficacies. The titers (3C1 > 3D3 = 3C2 > 2A10)
of these novel mAbs determined by IFA using a whole malaria parasite (sporozoite), as an antigen,
corroborate their protection efficacies in vitro (3C1 > 3D3 > 3C2 > 2A10), as well as in mice (3C1 > 3D3 =
3C2 > 2A10). These indicate that mAbs having higher titers against the native from of the CSP
expressed by sporozoites exert higher protection efficacies.
Synthesized peptides and sporozoites were used in ELISA and IFA, respectively, to determine
the antibody titers. Sporozoites express a native form of the PfCSP, whereas synthesized peptides
represent the primary structure of PfCSP. B-cell epitopes are typically classified as either linear epitopes
or conformational epitopes, which constitute the spatially folded amino acids and lie far away in
the primary sequence. The difference seen by ELISA and IFA may reflect the structural properties of
unique B-cell epitopes recognized by our mAbs.
Over the past few years, there has been growing interest in use of vectored immunoprophylaxis
to protect hosts from HIV. Vectored immunoprophylaxis is based on adeno-associated virus
(AAV) as a vehicle for generating the existing anti-HIV neutralizing antibodies in humans [29,30].
Recently vectored immunoprophylaxis has been utilized for other diseases including malaria and
colorectal cancer [12,31]. This new tool requires potent neutralizing antibodies. Although human
monoclonal antibodies against PfCSP have been generated, only one mouse mAb against PfCSP, 2A10,
has been used as a gold standard mAb for more than three decades. It is noteworthy that a few new
mouse mAbs against PfCSP, which we generated in this study, are found to be more potent than 2A10.
Therefore, we believe it is important to assess the characteristics of these newly generated mAbs before
humanizing them for the purpose of clinical applications, such as a vectored immunoprophylaxis, in
the future. Moreover, the mouse mAbs generated in this study are useful tools for the study of PfCSP
in a mouse model.
5. Conclusions
In summary, here we report a generation of novel mAbs specific against the CSP from P. falciparum.
The mAbs 2D4, 4C1, and 4C6 recognize the C-terminal region of PfCSP. The mAbs 3C1, 3C2, and 3D3
recognize the central repeat region of PfCSP, and their titers and protection efficacies are higher than
2A10, which has been widely used as a gold standard antibody against PfCSP.
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